Results 181 to 190 of about 181,578 (308)

Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination. [PDF]

Nat Commun
Warmuth L, Dötsch S, Trebo M, Bellucci S, Engels S, Valdivia Manrique R, Moukarzel K, Schütz JM, Hammel M, Straub A, Wagner S, Hochholzer A, Salinno C, Seigner J, Zajc CU, Schmidt GP, Michael J, Nerreter T, Hudecek M, Traxlmayr MW, Casucci M, Riddell SR, Poltorak MP, Busch DH, D'Ippolito E.   +24 more
europepmc   +1 more source

Nonviral Gold Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells

Advanced NanoBiomed Research, EarlyView.
CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham, Karthikeya S. V. Gottimukkala, Daniel D. Lane, Katrina Poljakov, Patricia Lipson, Mark R. Enstrom, Alessandro Rizzi, Aude G. Chapuis, Jennifer E. Adair   +8 more
wiley   +1 more source

Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review. [PDF]

J Transl Med
Han Q, Zhang X, Chen L, Zhang Y.
europepmc   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus. [PDF]

Ann Hematol
Lang M, Peng L, Jiang N, Li M, Zhang Y, Zeng X, Zhou D.   +6 more
europepmc   +1 more source

Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma [PDF]

, 2017
Bartlett, Nancy L, et al,, Ghobadi, Armin   +2 more
core   +2 more sources

Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA‐Reporter Assay

Arthritis &Rheumatology, EarlyView.
Objective Immune complexes (ICs), formed by autoantigen and autoantibody, play a pathogenic role in systemic autoimmune diseases through stimulation of Fcγ receptors (FcγR). However, studies investigating bioactivity of circulating ICs across various diseases remain limited.
Koji Suzuki, Masaru Takeshita, Yuki Imai, Hiroyuki Fukui, Kazunori Furuhashi, Kotaro Matsumoto, Jun Kikuchi, Keiko Yoshimoto, Yuko Kaneko   +8 more
wiley   +1 more source

Involvement of the hospital pharmacist in securing the chimeric antigen receptor (CAR)-T cell circuit. [PDF]

Eur J Hosp Pharm
Bryla A, Lorent S, Vervacke A, Scolas G, Alexandre L.   +4 more
europepmc   +1 more source

Autoantibodies to Joint‐Related Peptides Are Associated with Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals

Arthritis &Rheumatology, Accepted Article.
Objective To identify autoantibodies in presymptomatic individuals that associate with the onset of rheumatoid arthritis (RA), and to distinguish early RA from osteoarthritis (OA), particularly in individuals lacking classic RA serological markers. Methods We analyzed serum and plasma from three cohorts: pre‐symptomatic individuals who later developed ...
Outi Sareila, Linda Johansson, Anders Lundquist, Monica Leu Agelii, Lei Cheng, Yibo He, Erik Lönnblom, Maria Andersson, Jan Kihlberg, Anders Esberg, Inger Gjertsson, Rikard Holmdahl, Solbritt Rantapää‐Dahlqvist   +12 more
wiley   +1 more source

Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]

HLA
Schenk HCM, Gille I, Arana C, Rovira J, Palou E, Diekmann F, Roelen DL, Heemskerk MHM, Heidt S.   +8 more
europepmc   +1 more source